The answer almost assuredly is patient-specific, but the question of lipid-lowering as the end or the means in measuring cardiovascular risk highlights the ongoing discussion in medicine about targets: whether how we get there is more important than just getting there. Dr. Roger Blumenthal, professor of medicine in the division of cardiology at Johns Hopkins University School of Medicine, goes beyond a focus on lipid numbers in this discussion with host Dr. Larry Kaskel. As Dr. Blumenthal explains, cost-effectiveness is a critical consideration when examining target points in lipid therapy.
Brought to you by:
